Table 3.
Prognostic Factors for OS as Determined by Multivariate Analysis
| Variables | Standard Error | Wald | P value | HR | 95.0% CI for HR | |
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| Age | 0.130 | 2.571 | 0.109 | 0.812 | 0.630 | 1.047 |
| Gender | 0.180 | 0.001 | 0.976 | 0.995 | 0.699 | 1.415 |
| T stage | 0.119 | 0.204 | 0.652 | 1.055 | 0.835 | 1.334 |
| T0 | 6.965 | 0.138 | ||||
| T1 | 0.815 | 0.208 | 0.648 | 1.451 | 0.293 | 7.170 |
| T2 | 0.412 | 0.129 | 0.719 | 0.862 | 0.384 | 1.935 |
| T3 | 0.346 | 1.192 | 0.275 | 0.686 | 0.348 | 1.350 |
| T4 | 0.302 | 4.452 | 0.035 | 0.529 | 0.293 | 0.956 |
| N stage | 0.149 | 0.063 | 0.802 | 0.963 | 0.720 | 1.289 |
| M stage | 0.213 | 0.087 | 0.768 | 0.939 | 0.619 | 1.425 |
| BCLC staging | 0.109 | 0.007 | 0.934 | 0.991 | 0.800 | 1.227 |
| A | 3.517 | 0.319 | ||||
| B | 1.031 | 0.703 | 0.402 | 2.374 | 0.315 | 17.913 |
| C | 1.036 | 1.414 | 0.234 | 3.427 | 0.450 | 26.097 |
| D | 1.045 | 1.426 | 0.232 | 3.484 | 0.449 | 27.025 |
| NLR | 0.158 | 6.171 | 0.013 | 0.675 | 0.496 | 0.921 |
| PLR | 0.161 | 0.244 | 0.621 | 1.083 | 0.790 | 1.485 |
| MLR | 0.149 | 1.418 | 0.234 | 0.837 | 0.625 | 1.122 |
| LDH | 0.148 | 10.455 | 0.001 | 0.619 | 0.463 | 0.828 |
| ALP | 0.146 | 5.673 | 0.017 | 0.707 | 0.532 | 0.940 |
| CEA | 0.174 | 2.345 | 0.126 | 0.766 | 0.544 | 1.078 |
| Portal vein involvement | 0.176 | 14.561 | <0.001 | 0.511 | 0.362 | 0.721 |
| AFP | 0.134 | 3.721 | 0.054 | 0.773 | 0.595 | 1.004 |
Notes: P-values in bold were found to be significant.
Abbreviations: BCLC staging, Barcelona Clinic Liver Cancer staging; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; MLR, monocyte–lymphocyte ratio; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; CEA, carcinoembryonic antigen; AFP, α-fetoprotein; HR, hazard ratio; CI, confidential interval.